Tenderwize
Back to tender search

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 9 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke über 10.000 IE je Dosiereinheit)

70/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

70 / 100

Complexity

20 / 100

Risk factors

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 9 days

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Erythropoietin pharmaceuticals (ATC B03XA01, >10,000 IU per dose unit) under non-exclusive discount agreements.
  • Open-house model allowing any eligible pharmaceutical company to participate at any time.
Show full summary

This is an open-house model for non-exclusive discount agreements on Erythropoietin pharmaceuticals (strength >10,000 IU per dose unit) with AOK Sachsen-Anhalt. Any eligible pharmaceutical company can conclude a contract at any time under uniform conditions. The contract runs from earliest 01.11.2024 to 31.10.2026 (max 24 months). No estimated value or guaranteed volume is provided. The tender is not a public procurement under GWB but published for transparency.

Risks

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 9 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies.

Administrative

  • Must request and submit completed participation documents and signed contract.
  • Must meet uniform contract conditions (not specified in detail).

Award Criteria

Lot 1

No competitive award; contract available to all eligible participants.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

Conclusion of non-exclusive discount agreements for finished medicinal products containing Erythropoietin (ATC: B03XA01, strength >10,000 IU) under an open-house model. Any eligible pharmaceutical company can join at any time with standard contract terms. No exclusivity.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Award Criteria

No competitive award; contract available to all eligible participants.

Deadline

Deadline Aug 30, 2026

Procurement Details

Publication date
19 Sep 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
567828-2024

Documents (1)

Similar tenders